Provided herein are methods for predictinga likelihood of responsiveness to treatment with afolate receptor alpha (FRA)-targeting agent in a patienthaving a FRA-expressing lung cancer. Also provided aremethods for treating a FRA-expressing lung cancer in apatient with a FRA-targeting agent. The methods involvequantifying or determining the patient's FRA expressionlevel in a biological sample and comparing thepatient's FRA expression level to a reference standardused to quantify FRA expression level, wherein the patientis likely to respond to treatment with the FRA-targetingagent if the patient's FRA expression level equalsor exceeds the reference FRA expression level. Furtherprovided are related kits for prediction of response andtreatment of the identified population of FRA -expressinglung cancer patients.
